Taken together, these results suggest that this class of compounds might be useful in ovarian carcinoma as novel therapeutic agents, but it appears to be important to consider the level of expression of VEGFR2 and αVβ3 to target cells coexpressing both targets. Here, KDR is linked to ovarian carcinoma.